Manfred P. Wirth

Klinik und Poliklinik für Psychotherapie und Psychosomatik — Germany

Medicine · Health Sciences

59h-index15.6kcitations907works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(316), Prostate Cancer Diagnosis and Treatment(234), Bladder and Urothelial Cancer Treatments(184), Renal cell carcinoma treatment(92), Urinary and Genital Oncology Studies(76)

Publications903 total

Management of Localized Disease
2025
A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer
Molecular Medicine·2024· 5 citedOpen Access
Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?
European Urology Open Science·2023· 1 citedOpen Access
Untitled
International Archives of Urology and Complications·2023Open Access
1890P Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Annals of Oncology·2023Open Access
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)
European Urology·2023· 10 citedOpen Access
Characterization and evaluation of gene fusions as a measure of genetic instability and disease prognosis in prostate cancer
BMC Cancer·2023· 3 citedOpen Access
A paired-kidney allocation study found superior survival with HLA-DR compatible kidney transplants in the Eurotransplant Senior Program
Kidney International·2023· 16 citedOpen Access
Supplementary Table S3 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
2023Open Access
Supplementary Table S2 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
2023Open Access
Supplementary Table S4 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
2023Open Access
Supplementary Table and Figure Legend from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
2023Open Access
Supplementary Table S4 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
2023Open Access
Data from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
2023Open Access
Supplementary Figures S1-S10 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
2023Open Access
Supplementary Table and Figure Legend from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
2023Open Access
Supplementary Table S3 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
2023Open Access
Supplementary Table S1 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
2023Open Access
Supplementary Methods and Reference from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
2023Open Access
Supplementary Table S5 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
2023Open Access
page 1 of 46Next →

Frequent Co-authors

Susanne Fuessel(8), Axel Meye(7), Stefan Zastrow(7), Kurt Miller(6), Marc‐Oliver Grimm(6), Marieta Toma(6), David G. McLeod(5), Peter Iversen(5), William A. See(5), Gustavo Baretton(5), Ursula Steiner(4), Axel Hinke(4), Francesco Montorsi(4), Christian G. Stief(4), Shahrokh F. Shariat(4), Michael Froehner(4), Michael Froehner(4), Thomas Wiegel(3), Dirk Bottke(3), Alessandra Siegmann(3)